Know more

The vaccine candidate of the BioMAP team at INRAE-University of Tours (UMR Infectiology and Public Health) showed promising results during pre-clinical tests after two nasal immunisations done 3 weeks apart, both in terms of immune response as well as neutralisation of variants of the original virus. One of the advantages is therefore the prevention of the risk of contamination by a vaccinated individual. It is a vaccine based on viral proteins - Spike protein and viral proteins not subject to mutation - produced by the BioMAP team and encapsulated by the Biotech Vaxinano. The vaccine would therefore provide protection regardless of viral mutations and the circulating strain of coronavirus. This project is supported by a consortium comprising Recipharm, the Bio3 Institute, the University of Tours, the IMT Group and Vaxinano. It is financially supported by the ANR (National Research Agency), the Center-Val de Loire Region, the University of Tours and INRAE.

To find out more, here are some links :

- article in english : https://www.connexionfrance.com/French-news/Young-man-wearing-a-mask-using-a-nasal-spray 

- Article INRAE in french: https://www.inrae.fr/actualites/vaccin-100-francais-administrable-voie-nasale-contre-covid-19-resultats-pre-cliniques-positifs

- Video in french: https://www.youtube.com/watch?v=sSsvMi1bGOc